US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,208.60

-21.8735-1.78%

Number of Gainers:1

Number of Losers:5

Number of Flat:- -

PE:- -

High:1,242.12

Open:1,230.13

Low:1,201.81

Close:1,230.47

Loading ...

Teva (TEVA) Gets a Buy from Leader Capital Markets

Femasys Faces Nasdaq Noncompliance Notice for Stock Price

Femasys Inc. Faces Potential Delisting from Nasdaq Due to Noncompliance with Minimum Bid Price Requirement

Generation Bio Co. Announces 1-for-10 Reverse Stock Split Effective July 21, 2025

Generation Bio Announces 1-for-10 Reverse Stock Split

THOMSON REUTERS

Steven B. Binder, Director, Reports Disposal of Common Shares of MannKind Corporation

David Thomson, EVP Genl Counsel & Secretary, Reports Disposal of MannKind Corporation Common Shares

MannKind assumed with a Buy at H.C. Wainwright

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

Top Midday Gainers

MT Newswires Live

There Is A Reason Generation Bio Co.'s (NASDAQ:GBIO) Price Is Undemanding

Simply Wall St.

Crude Oil Moves Lower; Daré Bioscience Shares Jump

BUZZ-Daré Bioscience soars on birth control device trial data

Dare Bioscience Shares More Than Triple to $8.38 After Late Stage Data for Its Contraceptive Product

THOMSON REUTERS

Dare Bioscience Shares More Than Triple to $8.8 Premarket After Late Stage Data for Its Contraceptive Product

THOMSON REUTERS

Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene

Daré Bioscience Announces Positive Interim Phase 3 Results for Hormone-Free Contraceptive Ovaprene®

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

THOMSON REUTERS

Dare Bioscience Inc - Dsmb Recommends Continuation of Ovaprene Study Without Modification

THOMSON REUTERS

Dare Bioscience Inc: No New Safety or Tolerability Concerns Were Identified

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1208.6007,"timestamp":1752868799999,"preClose":1230.4742,"halted":0,"volume":20965516,"delay":0,"changeRate":-0.017777,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-21.873535,"latestTime":"07-18 16:00:00 EDT","open":1230.1279,"high":1242.116,"low":1201.8137,"amount":208566842.906942,"amplitude":0.032753,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.190645,"peRate":-14.470439,"turnoverRate":0.012689,"increases":1,"decrements":5,"flats":0,"marketCap":19728688996,"floatMarketCap":19593729512},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1242.116,"amplitude":0.032753,"preClose":1230.4742,"low":1201.8137,"pbRate":"3.190645","latestPrice":1208.6007,"volume":20965516,"delay":0,"open":1230.1279,"prevYearClose":1682.2216,"prevWeekClose":1234.1532,"prevMonthClose":1256.7808,"prevQuarterClose":1256.7808,"fiveDayClose":1234.1532,"twentyDayClose":1281.3877,"sixtyDayClose":1080.654,"secType":"PLATE","market":"US","turnoverRate":0.012689,"peRate":-14.470439,"marketCap":19728688996,"floatMarketCap":19593729512,"timestamp":1752868799999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":1,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552641376","title":"Teva (TEVA) Gets a Buy from Leader Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2552641376","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552641376?lang=en_us&edition=fundamental","pubTime":"2025-07-19 09:05","pubTimestamp":1752887112,"startTime":"0","endTime":"0","summary":"Leader Capital Markets analyst Sabina Levi maintained a Buy rating on Teva today and set a price target of ILA9,300.00. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/teva-teva-gets-a-buy-from-leader-capital-markets-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/teva-teva-gets-a-buy-from-leader-capital-markets-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","TEVA","BK4566","BK4596","BK4584","BK4559","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2552560418","title":"Femasys Faces Nasdaq Noncompliance Notice for Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2552560418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552560418?lang=en_us&edition=fundamental","pubTime":"2025-07-19 05:50","pubTimestamp":1752875439,"startTime":"0","endTime":"0","summary":"Femasys ( ($FEMY) ) has provided an update. On July 16, 2025, Femasys Inc. received a notice from Nasdaq indicating noncompliance with the Minimum ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/femasys-faces-nasdaq-noncompliance-notice-for-stock-price?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/femasys-faces-nasdaq-noncompliance-notice-for-stock-price?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2210150020.SGD","PSQ","BK4585","IE00B3QW5Z07.USD","TQQQ","LU2095319765.USD","BK4112","NDAQ","BK4584","QLD","TSYW.SI",".IXIC","NVIW.SI","USAW.SI","SQQQ","BK4082","USJW.SI","BK4539","MNQmain","LU2210149790.SGD","NQmain","FEMY","IE00B64PRP62.GBP","IE00BGHQF748.EUR","QID","IE00BKPKM429.USD","BK4588"],"gpt_icon":0},{"id":"2552649075","title":"Femasys Inc. Faces Potential Delisting from Nasdaq Due to Noncompliance with Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2552649075","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552649075?lang=en_us&edition=fundamental","pubTime":"2025-07-19 05:17","pubTimestamp":1752873422,"startTime":"0","endTime":"0","summary":"Femasys Inc. has announced a regulatory issue concerning its listing on The Nasdaq Stock Market. On July 16, 2025, the company received a notice of noncompliance with Nasdaq's Listing Rule 5550, as its common stock's minimum bid price has been below $1.00 per share for 30 consecutive business days. This notification, however, does not immediately affect the stock's current listing or trading status. Femasys has until January 12, 2026, to meet the Minimum Bid Price Requirement, which entails maintaining a bid price of at least $1.00 per share for ten consecutive business days. The company is considering options to regain compliance, such as a reverse stock split, although there is no assurance of success. If compliance is not achieved, Femasys may face delisting, but it may also seek a second compliance period if it meets other initial listing standards.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL3RW2fy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","FEMY","BK4584","BK4082"],"gpt_icon":0},{"id":"2552460233","title":"Generation Bio Co. Announces 1-for-10 Reverse Stock Split Effective July 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2552460233","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552460233?lang=en_us&edition=fundamental","pubTime":"2025-07-18 20:35","pubTimestamp":1752842109,"startTime":"0","endTime":"0","summary":"Generation Bio Co.  announced a 1-for-10 reverse stock split, effective at 5:00 pm ET on July 21, 2025. This move, approved by stockholders in June, aims to increase the per-share market price to comply with Nasdaq's listing requirements. The company's stock will trade on a split-adjusted basis starting July 22, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generation Bio Co. published the original content used to generate this news brief via GlobeNewswire  on July 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL8ns7qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4584","IE00B3QW5Z07.USD","BK4585","LU2095319765.USD","GBIO","LU2210150020.SGD","BK4139","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2552460907","title":"Generation Bio Announces 1-for-10 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2552460907","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552460907?lang=en_us&edition=fundamental","pubTime":"2025-07-18 20:35","pubTimestamp":1752842100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nTUA5NSZWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4584","GBIO"],"gpt_icon":0},{"id":"2552430137","title":"Steven B. Binder, Director, Reports Disposal of Common Shares of MannKind Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2552430137","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552430137?lang=en_us&edition=fundamental","pubTime":"2025-07-18 08:51","pubTimestamp":1752799904,"startTime":"0","endTime":"0","summary":"Steven B. Binder, a Director of MannKind Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL2Cv7vm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"gpt_icon":0},{"id":"2552965430","title":"David Thomson, EVP Genl Counsel & Secretary, Reports Disposal of MannKind Corporation Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2552965430","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552965430?lang=en_us&edition=fundamental","pubTime":"2025-07-18 08:46","pubTimestamp":1752799616,"startTime":"0","endTime":"0","summary":"David Thomson, EVP General Counsel & Secretary of MannKind Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL79TN0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"2551214283","title":"MannKind assumed with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2551214283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551214283?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:11","pubTimestamp":1752660667,"startTime":"0","endTime":"0","summary":"H.C. Wainwright assumed coverage of MannKind (MNKD) with a Buy rating and $9 price target The firm views the company’s pipeline as largely overlook...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mannkind-assumed-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mannkind-assumed-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2551131047","title":"Why Is Daré Bioscience Stock (DARE) Up 240% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2551131047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551131047?lang=en_us&edition=fundamental","pubTime":"2025-07-15 08:37","pubTimestamp":1752539820,"startTime":"0","endTime":"0","summary":"Daré Bioscience stock soared higher on Monday alongside positive interim data from a Phase 3 study.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-dare-bioscience-stock-dare-up-240-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-dare-bioscience-stock-dare-up-240-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4007","DARE"],"gpt_icon":0},{"id":"2551382751","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2551382751","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551382751?lang=en_us&edition=fundamental","pubTime":"2025-07-15 01:56","pubTimestamp":1752515782,"startTime":"0","endTime":"0","summary":"Zimmer Biomet (ZBH) signed a definitive agreement to acquire Monogram Technologies (MGRM) for a cash payment of $4.04 per common share, for a total equity value of about $177 million, the companies sa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029864427.USD","MGRM","IE00B19Z3B42.SGD","LU0708994859.HKD","IE0002270589.USD","IE00B19Z3581.USD","LU0889566641.SGD","LU1267930573.SGD","LU0792757196.USD","LU0310800379.SGD","BK4504","BK4566","IE00B7SZLL34.SGD","LU1267930813.SGD","LU0310799852.SGD","LU0211327993.USD","BK4585","LU0128525929.USD","LU1267930490.SGD","BK4007","BK4082","DARE","LU0006061336.USD","BK4139","BK4588","SONN","ZBH","BK4584","LU0211328371.USD"],"gpt_icon":1},{"id":"2551513672","title":"There Is A Reason Generation Bio Co.'s (NASDAQ:GBIO) Price Is Undemanding","url":"https://stock-news.laohu8.com/highlight/detail?id=2551513672","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551513672?lang=en_us&edition=fundamental","pubTime":"2025-07-15 01:37","pubTimestamp":1752514670,"startTime":"0","endTime":"0","summary":"With a price-to-sales (or \"P/S\") ratio of 1.1x Generation Bio Co. ( NASDAQ:GBIO ) may be sending very bullish signals...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gbio/generation-bio/news/there-is-a-reason-generation-bio-cos-nasdaqgbio-price-is-und","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","SQQQ",".IXIC","MNQmain","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","PSQ","NQmain","IE00BGHQF748.EUR","GBIO","TQQQ","QID","BK4584","IE00BKPKM429.USD","USJW.SI","BK4588","IE00B3QW5Z07.USD","BK4112","NDAQ","BK4139","USAW.SI","NVIW.SI","BK4585","TSYW.SI","LU2210149790.SGD"],"gpt_icon":1},{"id":"2551138803","title":"Crude Oil Moves Lower; Daré Bioscience Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2551138803","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551138803?lang=en_us&edition=fundamental","pubTime":"2025-07-15 01:09","pubTimestamp":1752512958,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/07/46399310/crude-oil-moves-lower-dare-bioscience-shares-jump","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBTX","IE00BYQQ9H92.USD","PSQ","BK4567","BK4584","TQQQ","BK4588","FAST","QID","BK4585","BK4139","BK4104","BK4157","DGNX","BK4023","MNQmain","NQmain","NVIW.SI","USAW.SI","DARE","USJW.SI","SQQQ","BK4204","IE00BFXG0V08.USD","QLD","IE00B5TLWC47.USD","BK4211","TSYW.SI",".IXIC","RYET","BK4007","BK4603"],"gpt_icon":1},{"id":"2551180390","title":"BUZZ-Daré Bioscience soars on birth control device trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2551180390","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551180390?lang=en_us&edition=fundamental","pubTime":"2025-07-14 23:54","pubTimestamp":1752508445,"startTime":"0","endTime":"0","summary":"BUZZ-DaréBioscience soars on birth control device trial data** Shares of women’s health firm Daré Bioscience DARE.O rise 88% to $4.72** Stock set for best day in over 5 years, if gains hold** Co says its medical device, Ovaprene, showed a pregnancy rate of about 9% among participants, in an ongoing late-stage study, in line with previous results** Ovaprene is an investigational, hormone-free, monthly intravaginal device to prevent pregnancy** An independent safety board reviewed the data and recommended the study continue without changes, co says** Vaginal odor was the main side effect, leading 17% of participants to leave the study** Ovaprene works by releasing a non-hormonal agent that slows sperm and uses a polymer barrier to block them from reaching the cervix** Including session moves, stock up 50% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB1DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DARE","BK4584"],"gpt_icon":0},{"id":"2551418177","title":"Dare Bioscience Shares More Than Triple to $8.38 After Late Stage Data for Its Contraceptive Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2551418177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551418177?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:31","pubTimestamp":1752499891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TB0NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","DARE","BK4007"],"gpt_icon":0},{"id":"2551768186","title":"Dare Bioscience Shares More Than Triple to $8.8 Premarket After Late Stage Data for Its Contraceptive Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2551768186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551768186?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:24","pubTimestamp":1752495868,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","DARE","BK4007"],"gpt_icon":0},{"id":"2551186306","title":"Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene","url":"https://stock-news.laohu8.com/highlight/detail?id=2551186306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551186306?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:05","pubTimestamp":1752494729,"startTime":"0","endTime":"0","summary":"Dare Bioscience (DARE) announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dare-reports-interim-safety-efficacy-results-from-phase-3-trial-of-ovaprene-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dare-reports-interim-safety-efficacy-results-from-phase-3-trial-of-ovaprene-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4007","DARE"],"gpt_icon":0},{"id":"2551618520","title":"Daré Bioscience Announces Positive Interim Phase 3 Results for Hormone-Free Contraceptive Ovaprene®","url":"https://stock-news.laohu8.com/highlight/detail?id=2551618520","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551618520?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:03","pubTimestamp":1752494588,"startTime":"0","endTime":"0","summary":"Daré Bioscience, Inc., a biopharmaceutical company, has announced positive interim results from its ongoing Phase 3 clinical trial of Ovaprene, an investigational hormone-free, monthly intravaginal contraceptive. The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene. Interim findings revealed that approximately 9% of participants experienced pregnancy, aligning with the company's expectations from previous studies. No serious safety concerns were identified, with favorable overall tolerability reported. The study's Data Safety Monitoring Board recommended continuing the trial without modifications. Final results and analysis of study endpoints, including the pregnancy rate calculated using the Pearl Index, are anticipated upon the study's completion. Currently, there are no FDA-approved hormone-free, monthly intravaginal contraceptives on the market.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDLbpydM0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4007","BK4584"],"gpt_icon":0},{"id":"2551918519","title":"Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive","url":"https://stock-news.laohu8.com/highlight/detail?id=2551918519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551918519?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:00","pubTimestamp":1752494405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TB137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4584","BK4007"],"gpt_icon":0},{"id":"2551851921","title":"Dare Bioscience Inc - Dsmb Recommends Continuation of Ovaprene Study Without Modification","url":"https://stock-news.laohu8.com/highlight/detail?id=2551851921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551851921?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:00","pubTimestamp":1752494405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TB137:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4584","BK4007"],"gpt_icon":0},{"id":"2551185153","title":"Dare Bioscience Inc: No New Safety or Tolerability Concerns Were Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2551185153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551185153?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:00","pubTimestamp":1752494405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TB137:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4584","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}